The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Regeneron Announces March 2011 Investor Conference Presentations

Wednesday, February 23, 2011

Regeneron Announces March 2011 Investor Conference Presentations09:30 EST Wednesday, February 23, 2011TARRYTOWN, N.Y., Feb. 23, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:Citi 2011 Global Healthcare Conference at 9:00 a.m. Eastern Time on Tuesday, March 1, 2011RBC Capital Markets' 2011 Healthcare Conference at 10:00 a.m. Eastern Time on Wednesday, March 2, 2011Cowen and Company 31st Annual Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, March 8, 2011Barclays Capital 2011 Global Healthcare Conference at 9:00 a.m. Eastern Time on Wednesday, March 16, 2011The sessions may be accessed through the Company?s web site, www.regeneron.com, on the Investor Relations page.  Archived versions of the presentations will be available for thirty days after the live webcasts.Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.Contact Information:Michael Aberman, M.D.Peter DworkinInvestor RelationsCorporate Communications914.345.7799914.345.7800michael.aberman@regeneron.competer.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.For further information: Michael Aberman, M.D., Investor Relations, +1-914-345-7799, michael.aberman@regeneron.com; or Peter Dworkin, Corporate Communications, +1-914-345-7800, peter.dworkin@regeneron.com